News
Press Releases
Ambros Therapeutics Launches with $125 Million Series A Financing to Advance Neridronate Through Phase 3 Registrational Program for Complex Regional Pain Syndrome Type 1
IRVINE, Calif. -- December 16, 2025 -- Ambros Therapeutics, Inc. today announced its launch as a clinical-stage biotechnology company advancing late-stage therapies for severe, underserved diseases beginning with neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1). Ambros launches with an oversubscribed $125 million Series A financing co-led by RA Capital Management and Patient Square Capital's platform Enavate Sciences, joined by Abiogen Pharma, Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital, Adage Capital Partners LP, and other dedicated life sciences investors.

Loading...